Abstract
This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI). 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues. Peak and mean concentrations of melphalan were significantly higher in plasma than in subcutaneous or tumour microdialysate. There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours. The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space. The model also accounted for the vascular dispersion of melphalan in the limb. Tumour response in the whole group to treatment was partial response: 53.8% (n= 7); complete response: 33.3% (n= 5); no response: 6.7% (n= 1). There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01). No significant relationship existed between the severity of toxic reactions in the limb or peak plasma creatine phosphokinase levels and peak melphalan microdialysate or plasma concentrations. It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI. The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation. The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Blochl-Daum B, Muller M, Meisinger V, Eichler HG, Fassolt A and Pehamberger H (1996) Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 73: 920–924
Creech O, Krementz E, Ryan R and Winblad J (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616–632
de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA and Eggermont AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000–1003
Duran GARCIAE, Santolaya R and Requena T (1999) Treatment of malignant melanoma. Ann Pharmacother 33: 730–738
Ekstrom PO, Andersen A, Saeter G, Giercksky KE and Slordal L (1997) Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Cancer Chemother Pharmacol 39: 267–272
Klaase JM, Kroon BB, Beijnen JH, van Slooten GW and van Dongen JA (1994) Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 70: 151–153
Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Fillippo F, Krementz ET, Ruiter D and Lejeune FJ (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16: 2906–2912
Lai D, Ingvar C and Thompson J (1993) The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1: 36–39
Landaw EM and DiStefano JJd (1984) Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 246: R665–R677
Mader RM, Brunner M, Rizovski B, Mensik C, Steger GG, Eichler HG and Muller M (1998) Analysis of microdialysates from cancer patients by capillary electrophoresis. Electrophoresis 19: 2981–2985
Muller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG and Blochl-Daum B (1997) 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57: 2598–2601
Muller M, Brunner M, Schmid R, Mader RM, Bockenheimer J, Steger GG, Steiner B, Eichler HG and Blochl-Daum B (1998) Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res 58: 2982–2985
Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ and Ruiter DJ (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 176: 279–287
Roberts MS, Donaldson JD and Rowland M (1988) Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm 16: 41–83
Scott RN, Blackie R, Kerr DJ, Hughes J, Burnside G, MacKie RM, Byrne DS and McKay AJ (1992) Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 11: 1811–1813
Sinha T and Benedict R (1996) Relationship between latitude and melanoma incidence: international evidence. Cancer Lett 99: 225–231
Thompson J, Waugh R, Saw R and Kam P (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7: 188–192
Thompson JF, Ramzan I, Kam P and Yau D (1996) Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Regional Cancer Treatment 9: 13–16
Thompson JF, Hunt JA, Shannon KF and Kam PC (1997) Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132: 903–907
Thompson JF, Kam PC, Waugh RC and Harman CR (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14: 238–247
Ungerstedt U (1991) Microdialysis—principles and applications for studies in animals and man. J Intern Med 230: 365–373
Vrouenraets BC, Kroon BB, Klaase JM, Nieweg OE, van Slooten GW and van Dongen JA (1995) Severe acute regional toxicity after normothermic or ‘mild’ hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 5: 425–431
Vrouenraets BC, Nieweg OE and Kroon BB (1996) Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83: 1319–1328
Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE and Kroon BB (1999) Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 188: 522–530
Weiss M, Kuhlmann O, Hung D and Roberts M (2000) Cytoplasmic binding and disposition kinetics of diclofenac in the isolated perfused rat liver. British Journal of Pharmacology,
Wieberdinck J, Benckhuysen C, Braat RP, van Slooten EA and Olthuis GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18: 905–910
Wu ZY, Thompson MJ, Roberts MS, Addison RS, Cannell GR, Grabs AJ and Smithers BM (1995) High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. J Chromatogr B Biomed Appl 673: 267–279
Wu Z, Roberts MS, Parsons PG and Smithers BM (1997a) Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. Melanoma Res 7: 19–26
Wu ZY, Smithers BM and Roberts MS (1997b) Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res 7: 252–264
Wu ZY, Smithers BM, Anderson C and Roberts MS (2000) Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?. Melanoma Res 10: 47–54
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Thompson, J., Siebert, G., Anissimov, Y. et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 85, 157–165 (2001). https://doi.org/10.1054/bjoc.2001.1902
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1902
Keywords
This article is cited by
-
Drug structure–transport relationships
Journal of Pharmacokinetics and Pharmacodynamics (2010)
-
Plasma and Tissue Pharmacokinetics of Epirubicin and Paclitaxel in Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Primary Breast Cancer
Clinical Pharmacology & Therapeutics (2007)